InspireMD begins pivotal study of CGuard Prime in TCAR procedures
| NSPR Stock | USD 3.00 0.02 0.67% |
Slightly above 51% of InspireMD's investor base is interested to short. The analysis of overall sentiment of trading InspireMD stock suggests that many investors are impartial at this time. InspireMD's investing sentiment overview a quick insight into current market opportunities from investing in InspireMD. Many technical investors use InspireMD stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
InspireMD |
InspireMD enrolled the first patient in its CGUARDIANS II pivotal study, which will evaluate the CGuard Prime Carotid Stent System.
Read at massdevice.com
 |
InspireMD Fundamental Analysis
We analyze InspireMD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InspireMD using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InspireMD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
InspireMD is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
InspireMD Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with InspireMD stock to make a market-neutral strategy. Peer analysis of InspireMD could also be used in its relative valuation, which is a method of valuing InspireMD by comparing valuation metrics with similar companies.
Peers
InspireMD Related Equities
| VVOS | Vivos Therapeutics | 6.87 | ||||
| SGHT | Sight Sciences | 6.25 | ||||
| TIVC | Tivic Health | 5.00 | ||||
| NPCE | Neuropace | 3.50 | ||||
| LNSR | LENSAR | 2.67 | ||||
| AIMD | Ainos | 2.27 | ||||
| SRDX | SurModics | 0.40 | ||||
| RSLS | ReShape Lifesciences | 0.45 | ||||
| NUWE | Nuwellis | 0.99 | ||||
| BJDX | Bluejay Diagnostics | 1.54 | ||||
| BBLG | Bone Biologics | 3.81 | ||||
| IRIX | IRIDEX | 4.09 | ||||
| TNON | Tenon Medical | 4.17 | ||||
| SSKN | STRATA Skin | 5.25 | ||||
| RPID | Rapid Micro | 10.00 |
Additional Tools for InspireMD Stock Analysis
When running InspireMD's price analysis, check to measure InspireMD's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InspireMD is operating at the current time. Most of InspireMD's value examination focuses on studying past and present price action to predict the probability of InspireMD's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InspireMD's price. Additionally, you may evaluate how the addition of InspireMD to your portfolios can decrease your overall portfolio volatility.